Veru (VERU) Other Accumulated Expenses (2010 - 2024)
Veru (VERU) posted quarterly Other Accumulated Expenses of $2.4 million for Q1 2024, down 13.73% year-over-year from $2.8 million in Q2 2023, and up 16.38% quarter-over-quarter from $2.1 million in Q4 2023.
Veru (VERU) Other Accumulated Expenses (2010 - 2024) Analysis & Trends
Veru (VERU) has reported Other Accumulated Expenses for 15 consecutive years, with $2.4 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Other Accumulated Expenses fell 13.73% year-over-year to $2.4 million; the TTM figure through Mar 2024 stood at $2.4 million (down 13.73% YoY), while the FY2023 annual figure was $2.0 million, down 11.66% from the prior year.
- Other Accumulated Expenses rose to $2.4 million in Q1 2024 per VERU's latest filing, from $2.1 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $7.0 million in Q4 2022 and bottomed at $1.2 million in Q3 2020.
- Historically, Other Accumulated Expenses has averaged $2.3 million across 5 years, with a median of $2.1 million in 2021.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 342.22% — and 2023, when it plunged 70.35%.
- Veru's Other Accumulated Expenses stood at $2.1 million in 2020, then decreased by 24.38% to $1.6 million in 2021, then surged by 342.22% to $7.0 million in 2022, then sank by 70.35% to $2.1 million in 2023, then advanced by 16.38% to $2.4 million in 2024.
- Business Quant data shows VERU's Other Accumulated Expenses at $2.4 million in Q1 2024, $2.1 million in Q4 2023, and $2.0 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 2.43 Mn |
| Dec 31, 2023 | 2.08 Mn |
| Sep 30, 2023 | 1.99 Mn |
| Jun 30, 2023 | 2.79 Mn |
| Mar 31, 2023 | 2.81 Mn |
| Dec 31, 2022 | 7.03 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 2.13 Mn |
| Mar 31, 2022 | 2.19 Mn |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 1.62 Mn |
| Jun 30, 2021 | 2.10 Mn |
| Mar 31, 2021 | 1.97 Mn |
| Dec 31, 2020 | 2.10 Mn |
| Sep 30, 2020 | 1.18 Mn |
| Jun 30, 2020 | 1.75 Mn |
| Mar 31, 2020 | 1.78 Mn |
| Dec 31, 2019 | 2.13 Mn |
| Sep 30, 2019 | 1.44 Mn |
| Jun 30, 2019 | 2.40 Mn |